°üÀýÅë ÁÖ»ç ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼ : Á¦Ç°º°, °üÀý À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2032³â)
Joint Pain Injections Market Share, Size, Trends, Industry Analysis Report, By Product ; By Joint Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è °üÀýÅë ÁÖ»ç ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 123¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
°üÀýÅëÁõ ÁÖ»çÀÇ ÀûÀÀÁõ È®´ë´Â Å« ±âȸ°¡ ÀÖ½À´Ï´Ù. ÇöÀç °üÀýÅë ÁÖ»ç´Â °ñ°üÀý¿° ¹× °ü·Ã Áúȯ¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¿¬±¸ °³¹ß ³ë·ÂÀ» ÅëÇØ °Ç¿°, Ȱ¾×³¶¿° ¹× ±âŸ ±Ù°ñ°Ý°è Áúȯ°ú °°Àº ´õ ³ÐÀº ¹üÀ§ÀÇ °üÀý ÁúȯÀ» Ä¿¹öÇÒ ¼ö ÀÖ´Â »õ·Î¿î ÀûÀÀÁõÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù.
´ÙÁß Ç÷¼ÒÆÇ Ç÷Àå(PRP), Áٱ⼼Æ÷ Ä¡·á, È÷¾Ë·ç·Ð»ê À¯µµÃ¼ µî »ý¹°ÇÐÀû °üÀýÅë ÁÖ»çÀÇ °³¹ß ¹× »ç¿ëÀº ÁÖ¸ñÇÒ ¸¸ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦ ÁÖ»ç´Â Àç»ý °¡´É¼ºÀÌ ÀÖ¾î Á¶Á÷ ȸº¹°ú Ä¡À¯¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. °üÀýÅë ÁÖ»ç ½ÃÀå¿¡ »ý¹°ÇÐÀû Á¦Á¦¸¦ µµÀÔÇÏ¸é Æ¯È÷ °üÀý Áúȯ¿¡ ´ëÇÑ Àç»ý ¼Ö·ç¼ÇÀ» ¿øÇϴ ȯÀڵ鿡°Ô Áøº¸ÀûÀ̰í ÀüüÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
°³º° ¸ÂÃã ÀÇ·á´Â ´Ù¾çÇÑ ÇコÄÉ¾î ºÐ¾ß¿¡¼ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ƯÁ¤ °üÀý »óÅÂ, º´·Â, À¯ÀüÀû ¿äÀο¡ µû¶ó ȯÀÚ °³°³ÀÎÀÇ °üÀýÅë Áֻ縦 ¸ÂÃãÈÇϸé Ä¡·á °á°ú¸¦ Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº ¾à¹° ¼±ÅÃ, º¹¿ë·®, Ä¡·á °èȹÀ» ¸ÂÃãÈÇÔÀ¸·Î½á °üÀýÅë ÁÖ»çÀÇ È¿°ú¸¦ ÃÖÀûÈÇϰí ȯÀÚ¿¡°Ô ¸ÂÃãÈµÈ °í±Þ ÅëÁõ °ü¸® ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
Æ÷½ºÆ® Äڷγª ½Ã´ë¿¡´Â ¿ø°Ý ÀÇ·á¿Í °¡»ó ÀÇ·á »ó´ãÀÌ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚµéÀº °üÀýÅë ¹®Á¦¸¦ ¿ø°ÝÀ¸·Î »ó´ãÇÏ´Â °ÍÀ» Á¡Á¡ ´õ ¼±È£Çϰí ÀÖÀ¸¸ç, ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü´Â °üÀýÅë Æò°¡, Áø´Ü ¹× ÁÖ»ç ó¹æ¿¡ ¿ø°Ý ÀǷḦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕÀº ÆíÀǼºÀ» Á¦°øÇÏ°í ´ë¸é Áø·áÀÇ Çʿ伺À» ÁÙ¿©ÁÖ¸ç, ÆÒµ¥¹ÍÀ¸·Î ÀÎÇÑ È¯ÀÚµéÀÇ ¼±È£µµ º¯È¿Íµµ ÀÏÄ¡ÇÕ´Ï´Ù.
ȯÀÚ °æÇèÀº Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü´Â ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀ̴ ȯÀÚ Áß½ÉÀÇ È¯°æÀ» Á¶¼ºÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½Ä¿¡´Â °ÈµÈ Ä¿¹Â´ÏÄÉÀ̼Ç, ¸ÂÃã Ä¡·á °èȹ, °üÀýÅë Áֻ縦 ¿øÇϴ ȯÀÚ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Áö¿ø µîÀÌ Æ÷ÇԵ˴ϴÙ.
°üÀýÅë ÁÖ»ç ½ÃÀå º¸°í¼ - ÁÖ¿ä ³»¿ë
È÷¾Ë·ç·Ð»ê ÁÖ»ç´Â ÅëÁõ ¿ÏÈ ¹× °üÀý °³¼±À» À§ÇÑ ºñ¼ö¼úÀû ´ë¾È¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó °¡Àå Å« ºÎ¹®À¸·Î ºÎ»óÇß½À´Ï´Ù.
³ôÀº ¹«¸ °ü·Ã Áúȯ À¯º´·ü, Àúħ½ÀÀû Ä¡·á ¼±È£µµ, ȯÀÚµéÀÇ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ¹«¸ÀÌ °¡Àå Å« ºÎ¹®À¸·Î ºÎ»ó
ÁÖ·Î ¼ÒºñÀÚ ¼ö¿ä Áõ°¡, ÆíÀǼº, Á¢±Ù¼º, ÀüÀÚ»ó°Å·¡¿ÍÀÇ ÅëÇÕÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.
ºÏ¹Ì´Â Àα¸ °í·ÉÈ, °ñ°üÀý¿°°ú °°Àº °üÀý °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡, ºñ¼ö¼úÀû Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ °üÀýÅë ÁÖ»ç ½ÃÀå ÀλçÀÌÆ®
- °üÀýÅë ÁÖ»ç ½ÃÀå - °üÀý À¯Çü ÇöȲ
- °üÀýÅë ÁÖ»ç ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
- ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
- PESTEL ºÐ¼®
- °üÀýÅë ÁÖ»ç ½ÃÀå °üÀý À¯Çü µ¿Çâ
- ¹ë·ùüÀÎ ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦5Àå ¼¼°èÀÇ °üÀýÅë ÁÖ»ç ½ÃÀå, Á¦Ç°º°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÁÖ»ç
- È÷¾Ë·ç·Ð»ê ÁÖ»ç
- Ç÷¼ÒÆÇdzºÎÇ÷Àå ÁÖ»ç
- Áٱ⼼Æ÷ ÁÖ»ç
- ±âŸ
Á¦6Àå ¼¼°èÀÇ °üÀýÅë ÁÖ»ç ½ÃÀå, À¯Åë ä³Îº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- ¼Ò¸Å ¾à±¹
- º´¿ø ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦7Àå ¼¼°èÀÇ °üÀýÅë ÁÖ»ç ½ÃÀå, °üÀý À¯Çüº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- Èü
- ½½
- ¾î±ú¿Í ÆÈ²ÞÄ¡
- ¼Õ°ú ¼Õ¸ñ
- ±âŸ
Á¦8Àå ¼¼°èÀÇ °üÀýÅë ÁÖ»ç ½ÃÀå, Áö¿ªº°
- ÁÖ¿ä Á¶»ç °á°ú
- ¼·Ð
- °üÀýÅë ÁÖ»ç ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
- °üÀýÅë ÁÖ»ç ½ÃÀå - ºÏ¹Ì
- ºÏ¹Ì : °üÀýÅë ÁÖ»ç ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ºÏ¹Ì : °üÀýÅë ÁÖ»ç ½ÃÀå, °üÀý À¯Çüº°, 2019-2032³â
- ºÏ¹Ì : °üÀýÅë ÁÖ»ç ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¹Ì±¹
- °üÀýÅë ÁÖ»ç ½ÃÀå - ij³ª´Ù
- °üÀýÅë ÁÖ»ç ½ÃÀå - À¯·´
- À¯·´ : °üÀýÅë ÁÖ»ç ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- À¯·´ : °üÀýÅë ÁÖ»ç ½ÃÀå, °üÀý À¯Çüº°, 2019-2032³â
- À¯·´ : °üÀýÅë ÁÖ»ç ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¿µ±¹
- °üÀýÅë ÁÖ»ç ½ÃÀå - ÇÁ¶û½º
- °üÀýÅë ÁÖ»ç ½ÃÀå - µ¶ÀÏ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ÀÌÅ»¸®¾Æ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ½ºÆäÀÎ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ³×´ú¶õµå
- °üÀýÅë ÁÖ»ç ½ÃÀå - ·¯½Ã¾Æ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾ç : °üÀýÅë ÁÖ»ç ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ¾Æ½Ã¾ÆÅÂÆò¾ç : °üÀýÅë ÁÖ»ç ½ÃÀå, °üÀý À¯Çüº°, 2019-2032³â
- ¾Æ½Ã¾ÆÅÂÆò¾ç : °üÀýÅë ÁÖ»ç ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
- °üÀýÅë ÁÖ»ç ½ÃÀå - Áß±¹
- °üÀýÅë ÁÖ»ç ½ÃÀå - Àεµ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¸»·¹À̽þÆ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ÀϺ»
- °üÀýÅë ÁÖ»ç ½ÃÀå - Àεµ³×½Ã¾Æ
- °üÀýÅë ÁÖ»ç ½ÃÀå - Çѱ¹
- °üÀýÅë ÁÖ»ç ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °üÀýÅë ÁÖ»ç ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °üÀýÅë ÁÖ»ç ½ÃÀå, °üÀý À¯Çüº°, 2019-2032³â
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : °üÀýÅë ÁÖ»ç ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
- °üÀýÅë ÁÖ»ç ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- °üÀýÅë ÁÖ»ç ½ÃÀå - À̽º¶ó¿¤
- °üÀýÅë ÁÖ»ç ½ÃÀå - ³²¾ÆÇÁ¸®Ä«
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä« : °üÀýÅë ÁÖ»ç ½ÃÀå, Á¦Ç°º°, 2019-2032³â
- ¶óƾ¾Æ¸Þ¸®Ä« : °üÀýÅë ÁÖ»ç ½ÃÀå, °üÀý À¯Çüº°, 2019-2032³â
- ¶óƾ¾Æ¸Þ¸®Ä« : °üÀýÅë ÁÖ»ç ½ÃÀå, À¯Åë ä³Îº°, 2019-2032³â
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¸ß½ÃÄÚ
- °üÀýÅë ÁÖ»ç ½ÃÀå - ºê¶óÁú
- °üÀýÅë ÁÖ»ç ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª
Á¦9Àå °æÀï ±¸µµ
- È®Àå ¹× Àμö ºÐ¼®
- Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦10Àå ±â¾÷ °³¿ä
- AbbVie Inc
- Alkem Laboratories
- Anika Therapeutics
- Bioventus
- Eli Lilly and Company
- Ferring Pharmaceuticals
- GlaxoSmithKline(GSK)
- Johnson & Johnson
- Merck
- Pacira BioSciences, Inc.
- Pfizer
- Sanofi
- Seikagaku Corporation
- Teva Pharmaceuticals
- Zimmer Biomet
LSH
The global joint pain injections market size is expected to reach USD 12.36 billion by 2032, according to a new study by Polaris Market Research. The report "Joint Pain Injections Market Share, Size, Trends, Industry Analysis Report, By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet-Rich Plasma Injections, Stem Cell Injections, Others); By Joint Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
There is a significant opportunity to expand the indications for joint pain injections. Currently, these injections are used for osteoarthritis and related conditions. However, research and development efforts are exploring new indications, potentially covering a broader range of joint conditions, such as tendinitis, bursitis, and other musculoskeletal disorders.
The development and use of biologic joint pain injections, including platelet-rich plasma (PRP), stem cell therapies, and hyaluronic acid derivatives, present a notable growth opportunity. Biologic injections have regenerative potential and can stimulate tissue repair and healing. Incorporating biologics into the joint pain injection market introduces advanced and holistic treatment options, particularly for patients seeking regenerative solutions for their joint conditions.
Personalized medicine is gaining prominence across various healthcare sectors. Tailoring joint pain injections to individual patients based on their specific joint condition, medical history, and genetic factors significantly enhances treatment outcomes. By customizing the choice of medication, dosage, and treatment plan, healthcare providers optimize the effectiveness of joint pain injections and deliver highly tailored pain management solutions to patients.
The adoption of telemedicine and virtual healthcare consultations has become more widespread in the post-COVID era. Patients are increasingly open to discussing joint pain issues remotely, and healthcare providers are leveraging telemedicine to evaluate, diagnose, and prescribe joint pain injections. This integration offers convenience and reduces the need for in-person visits, which aligns with pandemic-induced changes in patient preferences.
The patient experience has gained significance. Healthcare providers are focusing on creating a patient-centered environment that fosters trust and satisfaction. This approach includes enhanced communication, personalized care plans, and comprehensive support for individuals seeking joint pain injections.
Joint Pain Injections Market Report Highlights
Hyaluronic acid injections emerged as the largest segment on account of greater demand for non-surgical alternatives for pain relief and joint improvement
Knee emerged as the largest segment on account of higher incidence of knee-related conditions, preference towards less invasive treatments, and increased patient awareness
Retail pharmacies held the maximum market revenue share in 2022, mainly due to growing consumer demand, convenience, easy access, and e-commerce integration
North America region dominated the market with a majority share in 2022, owing to an aging population, rising prevalence of joint-related conditions like osteoarthritis, and growing demand for non-surgical treatment options
The global key market players include: Anika Therapeutics, Bioventus, Eli Lilly and Company, Ferring Pharmaceuticals, and Pacira BioSciences, Inc., among others
Polaris Market Research has segmented the Joint Pain Injections market report based on product, joint type, distribution channel, and region:
Joint Pain Injections, Product Outlook (Revenue - USD Billion, 2019 - 2032)
- Corticosteroid Injections
- Hyaluronic Acid Injections
- Platelet-Rich Plasma Injections
- Stem Cell Injections
- Others
Joint Pain Injections, Joint Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Hip
- Knee
- Shoulder and Elbow
- Hand and Wrist
- Others
Joint Pain Injections, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Joint Pain Injections, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Joint Pain Injections Market Insights
- 4.1. Joint Pain Injections Market - Joint Type Snapshot
- 4.2. Joint Pain Injections Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Aging population, prevalence of joint disorders, and rise in demand for minimally invasive treatments
- 4.2.1.2. Advancements in biotechnology and innovative formulations
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Stringent regulatory approvals and compliance challenges
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Joint Pain Injections Market Joint Type Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Joint Pain Injections Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 5.3. Corticosteroid Injections
- 5.3.1. Global Joint Pain Injections Market, by Corticosteroid Injections, by Region, 2019-2032 (USD Billion)
- 5.4. Hyaluronic Acid Injections
- 5.4.1. Global Joint Pain Injections Market, by Hyaluronic Acid Injections, by Region, 2019-2032 (USD Billion)
- 5.5. Platelet-Rich Plasma Injections
- 5.5.1. Global Joint Pain Injections Market, by Platelet-Rich Plasma Injections, by Region, 2019-2032 (USD Billion)
- 5.6. Stem Cell Injections
- 5.6.1. Global Joint Pain Injections Market, by Stem Cell Injections, by Region, 2019-2032 (USD Billion)
- 5.7. Others
- 5.7.1. Global Joint Pain Injections Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Joint Pain Injections Market, by Distribution Channel
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 6.3. Retail Pharmacies
- 6.3.1. Global Joint Pain Injections Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)
- 6.4. Hospital Pharmacies
- 6.4.1. Global Joint Pain Injections Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
- 6.5. Online Pharmacies
- 6.5.1. Global Joint Pain Injections Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)
7. Global Joint Pain Injections Market, by Joint Type
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 7.3. Hip
- 7.3.1. Global Joint Pain Injections Market, by Hip, By Region, 2019-2032 (USD Billion)
- 7.4. Knee
- 7.4.1. Global Joint Pain Injections Market, by Knee, By Region, 2019-2032 (USD Billion)
- 7.5. Shoulder and Elbow
- 7.5.1. Global Joint Pain Injections Market, by Shoulder and Elbow, By Region, 2019-2032 (USD Billion)
- 7.6. Hand and Wrist
- 7.6.1. Global Joint Pain Injections Market, by Hand and Wrist, By Region, 2019-2032 (USD Billion)
- 7.7. Others
- 7.7.1. Global Joint Pain Injections Market, by Others, By Region, 2019-2032 (USD Billion)
8. Global Joint Pain Injections Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Joint Pain Injections Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Joint Pain Injections Market - North America
- 8.3.1. North America: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.3.2. North America: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.3.3. North America: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.4. Joint Pain Injections Market - U.S.
- 8.3.4.1. U.S.: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.3.5. Joint Pain Injections Market - Canada
- 8.3.5.1. Canada: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4. Joint Pain Injections Market - Europe
- 8.4.1. Europe: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.3. Europe: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.4. Joint Pain Injections Market - UK
- 8.4.4.1. UK: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.5. Joint Pain Injections Market - France
- 8.4.5.1. France: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.5.3. France: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.6. Joint Pain Injections Market - Germany
- 8.4.6.1. Germany: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.7. Joint Pain Injections Market - Italy
- 8.4.7.1. Italy: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.8. Joint Pain Injections Market - Spain
- 8.4.8.1. Spain: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.9. Joint Pain Injections Market - Netherlands
- 8.4.9.1. Netherlands: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.4.10. Joint Pain Injections Market - Russia
- 8.4.10.1. Russia: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5. Joint Pain Injections Market - Asia Pacific
- 8.5.1. Asia Pacific: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.4. Joint Pain Injections Market - China
- 8.5.4.1. China: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.4.3. China: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.5. Joint Pain Injections Market - India
- 8.5.5.1. India: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.5.3. India: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.6. Joint Pain Injections Market - Malaysia
- 8.5.6.1. Malaysia: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.7. Joint Pain Injections Market - Japan
- 8.5.7.1. Japan: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.8. Joint Pain Injections Market - Indonesia
- 8.5.8.1. Indonesia: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.5.9. Joint Pain Injections Market - South Korea
- 8.5.9.1. South Korea: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6. Joint Pain Injections Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.4. Joint Pain Injections Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.5. Joint Pain Injections Market - UAE
- 8.6.5.1. UAE: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.6. Joint Pain Injections Market - Israel
- 8.6.6.1. Israel: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.6.7. Joint Pain Injections Market - South Africa
- 8.6.7.1. South Africa: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7. Joint Pain Injections Market - Latin America
- 8.7.1. Latin America: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.4. Joint Pain Injections Market - Mexico
- 8.7.4.1. Mexico: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.5. Joint Pain Injections Market - Brazil
- 8.7.5.1. Brazil: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
- 8.7.6. Joint Pain Injections Market - Argentina
- 8.7.6.1. Argentina: Joint Pain Injections Market, by Product, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Joint Pain Injections Market, by Joint Type, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Joint Pain Injections Market, by Distribution Channel, 2019-2032 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. AbbVie Inc
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Alkem Laboratories
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Anika Therapeutics
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Bioventus
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Eli Lilly and Company
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Ferring Pharmaceuticals
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. GlaxoSmithKline (GSK)
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Johnson & Johnson
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Merck
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Pacira BioSciences, Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Pfizer
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Sanofi
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Seikagaku Corporation
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. Teva Pharmaceuticals
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
- 10.15. Zimmer Biomet
- 10.15.1. Company Overview
- 10.15.2. Financial Performance
- 10.15.3. Product Benchmarking
- 10.15.4. Recent Development